What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Up to 3 times CT041 autologous CAR T-cell injection infusion”In the company’s words, NCT04581473 on ClinicalTrials.gov
- Tested for
- Pancreatic Cancer (3 trials), Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
- Main trialPhase 1/2
- “An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic cancer”In the company’s words, NCT04581473 on ClinicalTrials.gov
- Other names
- Single Group Assignment · CAR T-cell injection
Other drugs for Pancreatic Cancer
- CAM2029Camurus AB · Phase 3
- Immuncell-LCGC Cell Corporation · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- XNW28012Evopoint Biosciences Inc. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- DaraxonrasibRevolution Medicines · Phase 3
Coming up1
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 18 Oct 2024 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | |
| Phase 1/2Active, not recruiting | 1 Jun 2025 | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | |
| Phase 1Recruiting | 31 Dec 2026 | A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026